Warning: There are an increasing number of fraudulent websites that impersonate ECCMID. We would like to alert all our members and delegates to possible scams and we strongly advise you to use only the official ECCMID online registration for your bookings.

Abstract Categories


  • 1a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)
  • 1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)
  • 1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibilit/resistance
  • 1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)
  • 1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (all aspects)
  • 1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)
  • 1g. Viral epidemiology – general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)
  • 1h. Antiviral drugs, treatment, susceptibility/resistance (other than respiratory viruses, herpesviruses, hepatitis & HIV)
  • 1i. Other
  • 2a. Tuberculosis and other mycobacterial infections (incl antimycobacterial drugs, treatment & susceptibility/resistance, diagnostics & epidemiology)
  • 2b. Severe sepsis, bacteraemia & endocarditis (incl host bio-markers)
  • 2c. Community-acquired respiratory infections
  • 2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections
  • 2e. Skin, soft tissue, bone & joint (excl prostheses) & central nervous system infections
  • 2f. Zoonotic bacterial diseases (incl foodborne and waterborne pathogens and One Health aspects)
  • 2g. Other intracellular or rare bacteria
  • 2h. Other
  • 3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives
  • 3b. Resistance surveillance & epidemiology: Gram-negatives
  • 3c. Susceptibility testing methods (incl assay validation and comparative studies, excl TB)
  • 3d. Resistance mechanisms (excl TB)
  • 3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)
  • 3f. Clinical outcome of resistant infections (excl trials of new drugs)
  • 3g. Spread of resistance incl reservoirs, ecology, mobile elements (excl nosocomial transmission)
  • 3h. Other
  • 4a. Diagnostic bacteriology – culture based and general microbiology
  • 4b. Lab management, automation and QC
  • 4c. MALTI-TOF and other proteomic methods
  • 4d. Molecular diagnostics (incl POCT and syndromic testing)
  • 4e. Strain typing and surveillance (methods other than genomics)
  • 4f. Whole genome sequencing (diagnostic, typing)
  • 4g. Microbiome studies (incl clinical and diagnostic studies, One Health aspects)
  • 4h. Clinical metagenomics
  • 4i. Bioinformatics tools & pipelines
  • 4j. Other
  • 5a. Mechanisms of action, new compounds, preclinical data & pharmacology of antibacterial agents
  • 5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring
  • 5c. New or repurposed antibacterial agents: clinical trials
  • 5d. Pharmacoepidemiology (incl economics and cost-effectiveness), improved prescribing and antibiotic stewardship (incl decision-support / prediction tools, behavioural aspects)
  • 5e. Safety and adverse effects of treatment
  • 5f. Other
  • 6a. Fungal disease epidemiology
  • 6b. Diagnostic mycology (incl molecular)
  • 6c. Antifungal drugs & treatment (incl clinical trials)
  • 6d. Antifungal resistance & susceptibility testing (incl surveillance)
  • 6e. Other
  • 7a. Diagnostic parasitology
  • 7b. Antiparasitic susceptibility & resistance
  • 7c. Antiparasitic drugs & treatment
  • 7d. Parasitic disease epidemiology
  • 7e. Travel medicine & migrant health
  • 7f. Food & water safety and environmental health
  • 7g. International & public health
  • 7h. Other
  • 8a. Intravascular catheter-related infections
  • 8b. Other foreign-body and implant infections
  • 8c. Surgical site infections
  • 8d. Healthcare-associated pneumonia
  • 8e. Hospital epidemiology, transmission, surveillance & screening (incl. environment)
  • 8f. Other healthcare associated infections (incl CDI)
  • 8g. Infection control interventions and trials (incl. microbiota transplantation)
  • 8h. Disinfection & biocides
  • 8i. Other
  • 9a. Microbial pathogenesis & virulence
  • 9b. Host-pathogen interaction (including basic microbiome studies)
  • 9c. Preclinical biofilm studies
  • 9d. Experimental and cellular microbiology
  • 9e. Other
  • 10a. Host genetics: infection susceptibility & immunodeficiency
  • 10b. Clinical epidemiology and treatment of infections in immunocompromised hosts
  • 10c. General vaccinology (incl. policy, social aspects)
  • 10d. Antiviral vaccines (excl influenza, respiratory and bloodborne viruses)
  • 10e. Antibacterial vaccines
  • 10f. Immune response to infection (excl sepsis biomarkers)
  • 10g. Other
  • 11a. Education and career
  • 11b. Publishing, ethics, other academic and professional affairs
  • 11c. Other
  • 12a. Basic science and virology
  • 12b. Epidemiology- local, regional, global
  • 12c. Clinical features, case management, outcome
  • 12d. Diagnostics
  • 12e. Drug development and treatment modalities (incl. clinical trials)
  • 12f. Immune response, immunomodulation
  • 12g. Vaccine development and trials
  • 12h. Infection control
  • 12i. Public health policy, mitigation
  • 12j. Preparedness and response
  • 12k. Other societal aspects (incl. economics)
  • 12l. Other
  • 21. New drugs
  • 22. Clinical trials
  • 23. Outbreaks and public health emergencies
  • 24. other